Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezogabine Dose-Optimization in Partial-Onset Seizures
NCT01721317Phase 4Terminated
- Sponsor
- GSK
- Start
- Dec 2012
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial of retigabine in focal onset seizure, sponsored by GSK. Primary endpoint: Percent Change in the 28-day Total Partial Seizure Frequency. Started Dec 2012; status: terminated.
02
Drugs
retigabine
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT01721317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01721317.